Skip to main content
. Author manuscript; available in PMC: 2023 Jan 24.
Published in final edited form as: Addict Biol. 2021 Dec 2;27(2):e13116. doi: 10.1111/adb.13116

Figure 4.

Figure 4.

In Study 2, whole brain voxel-wise analysis of Medication Group X Treatment Period X Condition resulted in VmPFC and Right striatum effects (p<.001, α<.05, FWE). Here we show change in fMRI Brain Responses to Stress and Alcohol Cues with Prazosin versus Placebo Chronic Treatment relative to Pre-treatment in targeted VmPFC and striatal regions of interest at the p<.01 threshold. The Prazosin group showed improved VmPFC function with chronic treatment relative to pre-treatment during stress cue exposure (shown in red) not seen in the Placebo group; while the Placebo group showed increased R Striatum response (shown in Red) to alcohol cues and blunted VmPFC (shown in blue) response to stress challenge not seen in the Prazosin group.